by Tyler Shaw | Jul 21, 2026 | Success Stories
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia At week 24 in the CORALreef Lipids and CORALreef HeFH trials, LIPFENDRA significantly reduced LDL-C by a... by kelsey@oswaldmarketing.com | Jun 30, 2025 | Success Stories
Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in two decades More than 2,000... 
by kelsey@oswaldmarketing.com | May 14, 2025 | Success Stories
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine Atzumi™ (dihydroergotamine (DHE)) nasal powder is the first and only DHE nasal powder for the acute treatment of migraine with or... 
by adam@design812.com | Sep 21, 2024 | Success Stories
The study drug Aimovig is now FDA Approved. MediSphere conducted this Migraine trial in 2015-2017. Welcome news to some of the millions of Americans who suffer from potentially debilitating migraine headaches! The new drug, Aimovig, was produced by Amgen and approved... 
by adam@design812.com | Sep 21, 2024 | Success Stories
On November 21st, 2016 the U.S. Food and Drug Administration approved SOLIQUA™ 100/33. SOLIQUA 100/33 is an injectable prescription medicine that contains 2 diabetes medicines, insulin glargine and lixisenatide, that may improve blood sugar (glucose) control in adults... 
by adam@design812.com | Sep 21, 2024 | Success Stories
Erenumab Co-Developed by Amgen and Novartis for Episodic Migraine PreventionPharmaceutical company, Amgen, has announced positive top-line results for erenumab from a global Phase 3, STudy to evaluate the efficacy and safety of erenumab in migRaIne preVEntion...